SCHEMBL2684046

SCHEMBL2684046

NC(Cc1ccccc1)C(=O)N1CCc2c(C(=O)O)cc(-c3ccncc3)cc21

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR142 Q7Z601 2/20 0.41
DPP4 P27487 7/20 0.41
DPP8 Q6V1X1 4/20 0.41
DPP9 Q86TI2 4/20 0.41
DPP7 Q9UHL4 4/20 0.41
HDAC8 Q9BY41 4/20 0.40
FAP Q12884 3/20 0.40
TSHR P16473 1/20 0.37
SMYD3 Q9H7B4 1/20 0.36
OPRK1 P41145 1/20 0.36
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36
ALPI P09923 1/20 0.36
PKM P14618 1/20 0.36
PTGS1 P23219 1/20 0.36
XIAP P98170 1/20 0.36
SLC7A5 Q01650 1/20 0.36
TACR1 P25103 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2683937 0.93 IKBKB (0.42) GPR142DPP4DPP8DPP9DPP7
SCHEMBL2683939 0.93 IKBKB (0.42) GPR142DPP4DPP8DPP9DPP7
SCHEMBL2684073 0.90 GPR142 (0.40) GPR142DPP4DPP8DPP9DPP7
SCHEMBL2684070 0.90 GPR142 (0.40) GPR142DPP4DPP8DPP9DPP7
SCHEMBL2684415 0.84 DPP4 (0.38) GPR142DPP4DPP8DPP9DPP7
SCHEMBL13258465 0.83 HDAC8 (0.37) GPR142DPP4DPP8DPP9DPP7
SCHEMBL2685605 0.82 HDAC8 (0.47) GPR142DPP4DPP8DPP9DPP7
SCHEMBL2685606 0.82 HDAC8 (0.47) GPR142DPP4DPP8DPP9DPP7
SCHEMBL2683886 0.82 NOTUM (0.40) GPR142DPP4DPP8DPP9DPP7
SCHEMBL2684740 0.82 DPP4 (0.37) GPR142DPP4DPP8DPP9DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 US claimed
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 US disclosed
WO-2010093849-A2 PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2010-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS IAPP, INSR, AMY2A GPR142 2779/4885DPP4 272/4885DPP8 789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.